Literature DB >> 34739462

An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy.

Tommaso Filippini1, Federico Zagnoli2, Matteo Bosi3, Maria Edvige Giannone4, Cristina Marchesi5, Marco Vinceti6.   

Abstract

BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to the a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection.
METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Italy, a country severely affected by the pandemic, basing our assessment on publicly available data, and calculating such measures during the first and second waves.
RESULTS: We found that province-specific crude case-fatality rate in the first wave (February-July 2020) had a median value of 12.0%. Data about infection-fatality rate was more difficult to compute, due to large underestimation of SARS-CoV-2 infection during the first wave when asymptomatic individuals were very rarely tested. However, when using as a reference population-based seroprevalence data for anti-SARS-CoV-2 antibodies collected in May-July 2020, we computed an infection-fatality rate of 2.2%. During the second wave (Sep-Dec 2020), when SARS-CoV-2 testing was greatly increased and extended to many asymptomatic individuals, we could only compute a 'hybrid' case/infection-fatality rate with a value of 2.2%, similar to the infection-fatality rate of the first wave.
CONCLUSIONS: Overall, this study allowed to assess the COVID-19 case- and infection-fatality rates in Italy before of variant spread and vaccine availability, confirming their high values compared with other airborne infections like influenza. Our findings for Italy were similar to those characterizing other Western European countries.

Entities:  

Mesh:

Year:  2021        PMID: 34739462      PMCID: PMC8851028          DOI: 10.23750/abm.v92iS6.12241

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


Introduction

The COVID-19 pandemic is one of the greatest medical challenges of the last century (1), especially for the possible clinical presentation as a severe and life-threatening disease (2), with limited therapeutic options, and long-term sequelae (3-5). Since the beginning, attempts to control the pandemic spread relied on public health measures such as social distancing, contact tracing, use of face masks and other protective gears (like googles or face shields in health care settings), and lockdowns with limitations of population mobility (6-10). Still in recent months that vaccines are available, the presence of virus variants and the possibility of reinfection are of great concern (11-13). Italy was the first Western country severely hit by the pandemic, with a widespread population involvement, especially in the North of the country during the first wave (14). Factors associated with increased susceptibility to COVID-19 onset and severity, following the infection with SARS-CoV-2, have been shown to be male sex, and presence of a comorbidity such as hypertension, diabetes, cardiovascular disease, or chronic lung disease (15,16). Also, environmental factors may play a role increasing COVID-19 susceptibility and severity (17-21) as also reported in previous studies carried out in Northern Italy suggesting a positive association between air pollutant levels with both SARS-CoV-2 incidence and COVID-19 mortality (22-24). During the 2020, Italy experienced two pandemic waves. The first wave started with the first diagnosed case on February 20, 2020 and lasted till end of June 2020, leading to the implementation of a tight lockdown from March 8 to May 4, 2020 (6). After a brief summer period characterized by light restrictions due to the very low number of newly diagnosed cases, from September 2020 cases rapidly increased again, leading to a second, lighter lockdown from November 6, 2020 (25). Since begin of the vaccination campaign in a few subjects in December 27, 2020 and during the 2021, Italy has experienced a subsequent third wave in February-May 2021 and a fourth one in the most recent period, although the last ones have been largely mitigated by the growing number of vaccinated people (26). Due to lack of a large availability of SARS-CoV-2 swab tests during the first wave, SARS-CoV-2 infection testing was limited to subjects with symptoms potentially related to COVID-19 as well to health professionals (27-29). From the end of the first lockdown, availability of SARS-CoV-2 swab tests greatly increased and, therefore, testing has been extended to asymptomatic and pauci-symptomatic subjects (30). In particular, drive-through facilities have been implemented in several Italian cities with up to 1000 daily tests (31). For this reason, number of SARS-CoV-2 infections was certainly underestimated during the first wave (14), as also confirmed by the nationwide seroprevalence data made available by the National Institute of Statistics based on a population-based survey conducted in May-July 2020 (32). As consequence, there are uncertainties and controversies about the severity of COVID-19 and namely its case-fatality rate (number of COVID-19 deaths divided by COVID-19 cases, i.e. the symptomatic subjects diagnosed with the disease) and infection-fatality rate (number of deaths divided by overall number of cases of SARS-CoV-2 infection, i.e. including both symptomatic and asymptomatic subjects), due to methodological issues (33). Such issues include the censoring when the outcome is still unknown at the time of the investigation, the occurrence of ascertainment biases (34-36), especially the underestimation SARS-CoV-2 infection and COVID-19 incidence during an emergency situation as during the pandemic spread, and heterogeneity in classifying the outcome, i.e. COVID-19 related deaths (37-41). In this study, we aimed at assessing COVID-19 fatality rates in Italy, focusing on case-fatality and infection-fatality rates during the first and second waves on a provincial level during the first year of the COVID-19 pandemic, when neither virus variants were present in the country nor the vaccination campaign had started yet (42,43).

Methods

We downloaded publicly available COVID-19 data from the website of the Civil Protection Agency (44) and National Institute of Statistics (45), collecting daily data flow that Italian regions had to mandatorily provide with a provincial level of detail. In detail, we used the number of newly diagnosed infections with SARS-CoV-2 (corresponding to the new positive tests of infection based on quantitative reverse transcription polymerase chain reaction) and number of COVID-19 deaths in two time frames: from February 24-June 30, 2020 (first wave), and from September 1-December 31, 2020 (second wave). We also used data about anti-SARS-CoV-2 antibody seroprevalence recently made available at a provincial level by a survey carried out by the National Institute of Statistics in May-July 2020 (32). In order to take into account possible differences in time-frame between the first wave period and the seroprevalence survey, we also considered as alternative first wave period February 24-July 31, 2020. We calculated the province-specific case-fatality rate, also called ratio (34,46), for the first and second waves by dividing the number of deaths by the number of diagnosed positive cases in the two periods February 24-June 30 and February 24-July 31, 2020. We then calculated the province-specific infection-fatality rate (34) by dividing the number of deaths occurred during the first wave (February 24-June 30, 2020) by the estimated number of seroprevalent subjects using data of the National Institute of Statistics carried out in the period May-July 2020 (32). We eventually computed the rate between deaths and positive molecular tests during the September 1-December 31 period, that we called ‘case/infection-fatality rate’ due to the hybrid nature of such indicator, whose denominator included asymptomatic and symptomatic SARS-CoV-2 infected cases due to nationwide marked changes in testing availability and policy (14). All these estimates were crude, i.e. unadjusted for age and sex. Using data made publicly available by the European Center for Disease Control (ECDC), we also retrieved COVID-19 cases and deaths occurred in all European countries during the 2020, available on a weekly basis (47). As we did with Italian provinces, we calculated the case-fatality rate and the case/infection- fatality rate for the first and second waves, respectively. For this purpose, we considered as first wave the time from the beginning of the virus spread up to summer period (June 30, 2020) when cases waned in almost all countries (some countries experienced a unique wave in the 2020). The beginning of second wave was considered variable according to the raising of the curve up to the end of the year, generally January 1, 2021 based on the weekly availability of data (47). We also compared data of fatality rate of COVID-19 with seasonal flu. We retrieved data of flu cases through reports released by the National Institute of Health (48), while we used annual flu deaths available from the National Institute of Statistics (49). We excluded the most recent years, taking into account the influence of the COVID-19 pandemic in the circulation of other airborne infections (50). To investigate the relation between province-specific estimates, we used linear regression to fit a restricted cubic spline model with three knots at fixed percentiles (10th, 50th and 90th) of first wave distribution and weighted by the provincial population in 2020 (51). We used a multivariable model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident, available using 2011 census data of the National Institute of Statistics (51). We used the Stata statistical software (Version-17.0 Stata Corp., College Station-TX, 2021) for all analyses.

Results

Table 1 presents detailed information about number of cases and deaths divided by first and second waves along with seroprevalence data in the Italian provinces. In Italy, diagnosed cases and deaths during the first wave were 235,839 and 35,048, respectively. Corresponding values for the second wave were 1,808,260 cases and 40,392 deaths.
Table 1.

Number of SARS-CoV-2 cases, COVID-19 deaths, COVID-19 case-fatality rate (deaths/cases*100) in the first (1st) wave (February 24-June 30), and case/infection-fatality rate (deaths/cases*100) in the second (2nd) waves (September 30-December 31) in 2020 divided by province and region. SARS-CoV-2 seroprevalence (%) after the 1st wave (period May-July 2020) and infection-fatality rate (deaths/seroprevalents*100).

Region/ProvincePopulation Jan 1, 2020Cases 1st waveCases 2nd waveSeroprev. (%)Deaths 1st waveDeaths 2nd waveCase-fatality rate 1st waveInfection-fatality rate 1st waveCase/infection fatality rate 2nd wave
Aosta Valley 125501 1195 5771 3.72 145 239 12.1 3.1 4.1
Aosta125501119557713.7214523912.13.14.1
Lombardy 10103969 91813 368273 7.35 16633 8321 18.1 2.2 2.3
Bergamo1116384143751287324.3313719321.81.21.5
Brescia126845515626254687.63268642217.22.81.7
Como6038284093295312.0058779414.34.82.7
Cremona3583476612766419.7113012317.11.61.6
Lecco3370872831103036.6648123617.02.12.3
Lodi230607357069367.1067914019.04.12.0
Mantua4110623496122606.5768428819.62.52.3
Milan3279944243791477203.954252319717.43.32.2
Monza/Brianza8782675772420904.5297989517.02.52.1
Pavia5465155568188695.95124154322.33.72.9
Sondrio180941158469545.3021220113.42.22.9
Varese8925323907476051.71565128914.53.72.7
Veneto 4907704 18937 227276 1.92 2028 4960 10.7 2.1 2.2
Belluno2019721191133691.881143309.63.02.5
Padua9396723954416512.323186088.01.51.5
Rovigo23338644469322.39362048.10.62.9
Treviso8883092673457151.8932278312.01.91.7
Venice8516632682356121.6829986311.12.12.4
Verona9303395127440732.23586119511.42.82.7
Vicenza8623632866399241.3335397712.33.12.4
Emilia-Romagna 4467118 28061 137052 2.90 4353 3431 15.5 3.4 2.5
Bologna10178065229323142.3373293614.03.02.9
Ferrara344840104478860.7217322216.67.02.8
Forlì-Cesena3948331740102131.0419616411.34.81.6
Modena7072923873259451.1048060112.46.22.3
Parma453930365787015.8490121524.63.42.5
Piacenza2872364428101879.5495625221.63.52.5
Ravenna3896341030113371.18814307.91.83.8
Reggio nell’Emilia5317514913182484.4558130611.82.51.7
Rimini3397962147122212.7925330511.82.92.5
Piedmont 4341375 30989 162730 3.45 4029 3537 13.0 2.7 2.2
Alessandria4190374063132402.0865947016.27.73.5
Asti213216187479602.1324921713.35.52.7
Biella174384104657486.5919411218.51.71.9
Cuneo5865682862240810.8737349413.07.32.1
Novara3680402792124435.2136727213.11.92.2
Turin225237915889877883.581844171211.62.32.0
Verbano-Cusio-Ossola157455114055159.0513212211.60.92.2
Vercelli170296132359553.5221113815.93.52.3
Trentino-South Tyrol 1074819 7502 43303 3.19 693 1041 9.2 2.0 2.4
Bolzano5320802639265592.9528850410.91.81.9
Trento5427394863167443.424055378.32.23.2
Friuli-Venezia Giulia 1211357 3308 45651 1.02 362 1426 10.9 2.9 3.1
Gorizia13920621659040.1251042.3-1.8
Pordenone31261970297921.88682919.71.23.0
Trieste233276139391070.5920927015.0-3.0
Udine526256997208480.93807618.01.63.7
Liguria 1543127 9473 46958 3.24 1563 1276 16.5 3.1 2.7
Genoa8358295573293043.6194385316.93.12.9
Imperia213919149448062.392317915.54.51.6
La Spezia21919686071421.8915918918.53.82.6
Savona274183154657063.8323015514.92.22.7
Tuscany 3722729 9779 108429 0.90 1088 2491 11.1 3.3 2.3
Arezzo34176667697791.23471687.01.11.7
Florence10042983192298640.5340183912.67.52.8
Grosseto22078539637081.1828737.11.12.0
Livorno33350947780790.566219513.03.32.4
Lucca3886781351110100.4215119211.29.31.7
Massa and Carrara193934105164420.0015317914.6-2.8
Pisa422310930156671.55913419.81.42.2
Pistoia29305974796400.967619910.22.72.1
Prato25815253297901.02472038.81.82.1
Siena26623842744502.17321027.50.62.3
Umbria 880285 1385 26064 0.67 80 530 5.8 1.4 2.0
Perugia6554031008198430.71513695.11.11.9
Terni22488237762210.55291617.72.42.6
Marches 1518400 6549 33194 2.59 987 720 15.1 2.5 2.2
Ancona469750187597112.1621818511.62.11.9
Ascoli Piceno20636329047904.95121254.10.12.6
Fermo17300447343372.16676914.21.01.6
Macerata312146115478512.1614515912.62.22.0
Pesaro and Urbino357137275765054.9554518219.83.12.8
Lazio 5865544 8010 148533 1.00 863 2815 10.8 1.4 1.9
Frosinone485241663129900.197916211.98.61.2
Latina576655607136250.50442947.21.52.2
Rieti15423241145653.004114910.00.93.3
Rome433327458721089881.05672201611.41.41.8
Viterbo31614245783651.52271945.90.62.3
Abruzzo 1305770 3261 31124 1.29 461 794 14.1 2.7 2.6
Chieti38318981862841.4013113616.02.42.2
L’Aquila296491225106040.54113504.90.73.3
Pescara318678158654471.6923911615.14.42.1
Teramo30741263287891.488019212.71.82.2
Molise 302265 426 5971 0.81 28 175 6.6 1.1 2.9
Campobasso21867936438290.66221106.01.42.9
Isernia835866221421.196659.70.63.0
Campania 5785861 4648 182462 0.89 517 2915 11.1 1.0 1.6
Avellino41392655282890.006214311.2-1.7
Benevento27408020944230.00191379.1-3.1
Caserta922171543337411.48535409.80.41.6
Naples308290526521112941.04314181111.81.01.6
Salerno1092779692247150.316928410.02.11.1
Apulia 4008296 4502 84951 0.88 566 2037 12.6 1.6 2.4
Bari12492461491332371.5015363610.30.81.9
Barletta-Andria-Trani388390380100580.776629517.42.22.9
Brindisi39045665957950.856710010.22.01.7
Foggia6163101170186391.0216165513.82.63.5
Lecce79112252164200.018511416.3-1.8
Taranto572772281108020.673423712.10.92.2
Basilicata 556934 400 10055 0.72 36 214 9.0 0.9 2.1
Potenza36093618967390.832715614.30.92.3
Matera19599821133160.509584.30.91.7
Calabria 1924701 1179 22191 0.51 129 368 10.9 1.3 1.7
Catanzaro35485121431340.40314914.52.21.6
Cosenza70038546866760.784817610.30.92.6
Crotone17071811920650.1110358.45.21.7
Reggio di Calabria54127829485860.1829819.93.10.9
Vibo Valentia1574698417301.12112713.10.61.6
Sicily 4968410 3056 89352 0.37 342 2390 11.2 1.9 2.7
Agrigento42961113536510.192410717.83.02.9
Caltanissetta26077918637330.0018819.7-2.2
Catania1104974779264640.2610384913.23.63.2
Enna16236843828660.0034767.8-2.7
Messina620721474102460.325913612.42.91.3
Palermo1243328500249290.89436658.60.42.7
Ragusa3212158764900.3061616.90.62.5
Siracusa39703732151120.144716214.68.83.2
Trapani42837713658610.0081535.9-2.6
Sardinia 1630474 1366 28920 0.50 145 712 10.6 1.8 2.5
Cagliari43091425365730.38191617.51.22.4
Nuoro2068437860550.241212315.42.42.0
Oristano1560786124160.4385113.11.22.1
Sassari48963487589970.789024710.32.42.7
South Sardinia3470059948790.421613016.21.12.7
Italy 60244639 235839 1808260 2.49 35048 40392 14.9 2.2 2.2

†Provinces excluded due to implausible data of seroprevalences since the estimated number of seroprevalent subjects are less than the number of positive cases at the end of the first wave. ‡Provinces excluded due to missing/null data about seroprevalence.

Number of SARS-CoV-2 cases, COVID-19 deaths, COVID-19 case-fatality rate (deaths/cases*100) in the first (1st) wave (February 24-June 30), and case/infection-fatality rate (deaths/cases*100) in the second (2nd) waves (September 30-December 31) in 2020 divided by province and region. SARS-CoV-2 seroprevalence (%) after the 1st wave (period May-July 2020) and infection-fatality rate (deaths/seroprevalents*100). †Provinces excluded due to implausible data of seroprevalences since the estimated number of seroprevalent subjects are less than the number of positive cases at the end of the first wave. ‡Provinces excluded due to missing/null data about seroprevalence. National average seroprevalence was 2.49%, with the highest values in Bergamo (24.3%), Cremona (19.7%), and Piacenza (9.5%). Six provinces (Avellino, Benevento, Caltanissetta, Enna, Massa-Carrara and Trapani) reported null seroprevalence, while three provinces, Lecce, Gorizia and Trieste, showed extremely low and implausible seroprevalence rates. We considered these latter provinces as unwarranted outliers arising from a low and potentially highly biased participation in the survey since the estimated number of seroprevalent subjects is lower than the ascertained cases during the first wave. For this reason, we removed these provinces from the analyses concerning the infection-fatality rate. Figure 1 shows the case-fatality rate (from swab testing) and the infection-fatality rate (from seroprevalence data) in the first wave, and the case/infection-fatality rate (from swab testing) in the second wave across the Italian provinces. Overall in Italy, crude case-fatality rate was 14.9% for the first wave and 2.2% for the second wave, while the crude infection-fatality rate based on seroprevalence after the first wave was 2.2%. Province-specific values of case-fatality rate showed a median value of 12% (ranging from 2.3% in Gorizia to 24.6% in Parma), while the infection-fatality rate using seroprevalence data was much lower with a median value of 2.2%. During the second wave, SARS-CoV-2 testing greatly increased and was extended also to asymptomatic subjects, leading to a ‘mixed’ case/infection-fatality rate with median value of 2.2%, comparable to the infection fatality rate of 2.2% (Table 1).
Figure 1.

Crude case-fatality rate (deaths per 100 cases) for first wave (February 24-June 30, 2020), infection-fatality rate (deaths per 100 cases) after the first wave, and case/infection-fatality rate for the second (September 1-December 31, 2020) wave.

Crude case-fatality rate (deaths per 100 cases) for first wave (February 24-June 30, 2020), infection-fatality rate (deaths per 100 cases) after the first wave, and case/infection-fatality rate for the second (September 1-December 31, 2020) wave. In Table 2 we report SARS-CoV-2 cases and COVID-19 deaths occurred in European countries in 2020 divided in the two pandemic waves, and the case-fatality and case/infection-fatality rates in European countries for the first and second waves, respectively. Overall, Italy showed one of the highest first-wave case-fatality rate (14.43%) along with other severely hit countries such as France (18.22%), Belgium (15.48), and UK (14.15%) compared to the value of EE/EEA area (10.59%) (Table 2 and Figure 2). In the majority of European countries, the second wave began from August to mid-September 2020, with some exceptions reporting an earlier onset in July, namely France, Spain, Malta, and Ukraine, with consequent difficulties in the comparison. Overall in 2020, the EE/EEA area showed a fatality rate of 2.38%, with the highest values reported by Bulgaria (3.78%), Greece (3.54%), and Italy (3.49%).
Table 2.

Crude case-fatality (deaths per 100 cases) for the first (1st) wave for all EU/EEA countries (+ Switzerland and United Kingdom) from the beginning of the pandemic to June 30 if not differently specified, and case/infection-fatality rate (deaths per 100 cases) for the second (2nd) wave. Time-frame is different with the begin of the second wave indicated for each country, while the end was January 3, 2021 for all countries.

CountryTotal population 2020Cases 1st waveDeaths 1st waveCase-fatality 1st wave2nd wave time-frameCases 2nd waveDeaths 2nd waveCase/infection fatality 2nd waveTotal 2020 casesTotal 2020 deaths2020 fatality
Andorra76177855526.0814 Sep6848310.458192841.03
Austria8901064182697063.8614 Sep33123954971.6636457462531.72
Belgium1152244062394966015.4814 Sep55675999271.78651968198763.05
Bulgaria695148257402464.295 Oct18146468343.7720305176783.78
Croatia405816531511133.595 Oct19529937741.9321295840721.91
Cyprus8880051003191.8912 Oct219881060.48239741310.55
Czech Republic10693939125563522.8031 Aug722615120051.66747003124311.66
Denmark5822763128326064.727 Sep1511647470.4916871113740.81
Estonia13289761993633.1623 Oct251101780.71295212510.85
Finland552529272723094.257 Sep286282891.01369196071.64
France673202161640682989318.2227 Jul2457579348451.422636772650372.47
Germany8316671119655490164.597 Sep1524714252491.661775513345741.95
Greece1071856535191925.4610 Aug13447647453.5314009949573.54
Hungary9769526418358914.0831 Aug32289093632.9032885199773.03
Iceland3641341830100.5514 Sep3589190.535754290.50
Ireland49644402552717416.827 Sep722154820.6710188722592.22
Italy596414882416113486114.4331 Aug1887228398552.112155446753323.49
Latvia19076751124302.6721 Sep409726441.57424976801.60
Liechtenstein387478411.195 Oct2096341.622222351.58
Lithuania27940901836794.305 Oct14280218561.3014798719501.32
Luxembourg62610845221102.4314 Sep397253820.96469195061.08
Malta51456467191.3427 Jul125202081.66132192171.64
Monaco392447511.335 Oct68520.2990730.33
The Netherlands1740758550621612712.1031 Aug75012253830.72820193115981.41
Norway536758088952512.8219 Oct345791710.49507154490.89
Poland379581383595015174.2228 Sep1235617267292.161322947291612.20
Portugal102959094389716143.687 Sep37136553561.4443162371961.67
Romania193288382897317506.0421 Sep527648115442.19640429159792.50
San Marino34453698426.0212 Oct1741201.152493622.49
Slovakia54578731798281.5621 Sep30684826160.8531411726570.85
Slovenia209586117001116.537 Sep12268427612.2512585828912.30
Spain473326142517892838811.276 Jul1702891226721.331958844510782.61
Sweden103275897061255767.905 Oct36685842321.15462661101252.19
Switzerland86060333218416855.245 Oct40539754551.3545966072381.57
Ukraine437337594850012492.5820 Jul1015251173691.711074093188541.76
United Kingdom680598632871214063214.157 Sep2307627334731.452654779750242.83
EU/EEA countries 45309377 1264974 133967 10.59 - - - - 15963232 379360 2.38

† Population data from Eurostat (

Figure 2.

Map and histograms of case-fatality and case/infection-fatality during the first and second waves in EU/EEA countries (+ Switzerland and United Kingdom).

Crude case-fatality (deaths per 100 cases) for the first (1st) wave for all EU/EEA countries (+ Switzerland and United Kingdom) from the beginning of the pandemic to June 30 if not differently specified, and case/infection-fatality rate (deaths per 100 cases) for the second (2nd) wave. Time-frame is different with the begin of the second wave indicated for each country, while the end was January 3, 2021 for all countries. † Population data from Eurostat ( Map and histograms of case-fatality and case/infection-fatality during the first and second waves in EU/EEA countries (+ Switzerland and United Kingdom). In Table 3, we report data about cases of seasonal flu epidemics, and we computed an average case-fatality rate from past seasons of 0.01%, which is orders of magnitude lower of COVID-19 disease.
Table 3.

Number of influenza cases and deaths in Italy during the most recent seasonal flu epidemics.

SeasonFlu casesISTAT reportFlu deaths
2012/201359950002013417
2013/201445420002014272
2014/201562990002015675
2015/201648769002016316
2016/201754409002017663
2017/201886773002018745
Number of influenza cases and deaths in Italy during the most recent seasonal flu epidemics. When we compared the case-fatality rate of the first wave with the infection-fatality rate after the first wave using seroprevalence data in the Italian provinces using the spline analysis (Figure 3), we found a substantially linear positive association up to approximately 12% of case-fatality rate in the first wave corresponding to 3.6 infection-fatality rate, while the curve flattened at higher values.
Figure 3.

Comparison of first wave case-fatality rate (using positive swab data to estimate COVID-19 cases) and infection-fatality rate (using May-June seroprevalence data to estimate infected cases) considering the time frames February 24-June 30, 2020 (A) and February 24-July 31, 2020 (B). Spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.

Comparison of first wave case-fatality rate (using positive swab data to estimate COVID-19 cases) and infection-fatality rate (using May-June seroprevalence data to estimate infected cases) considering the time frames February 24-June 30, 2020 (A) and February 24-July 31, 2020 (B). Spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident. In the spline regression model comparing case-fatality rate in the first wave with the case/infection-fatality rate in the second wave, we did not find any relation between the two variables. On average, the case-fatality rate was 5.6 times 95% CIs (95% CI 5.2-6.1) higher in the first compared to the second wave (Figure 4).
Figure 4.

Comparison of first and second wave case-fatality rate in a spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.

Comparison of first and second wave case-fatality rate in a spline regression model adjusted for aging index, percentage commuting outside the municipality of residence on a daily basis, and percentage of dwellings occupied by only one resident.

Discussion

At the end 2020, Italy was one of the countries reporting the highest number of confirmed positive cases as well as COVID-19 deaths (52). Since many uncertainties still exist about the real impact and severity of COVID-19 pandemic (33,37,53,54), in the present investigation we provided an assessment of the COVID-19 case-fatality and infection-fatality rates during the 2020 in Italian provinces. Overall, our data confirmed that during the first wave, when almost all subjects underwent SARS-CoV-2 testing due to presence of symptoms related to COVID-19, the Italian case-fatality rate was as high as around 15%, being much higher than the infection-fatality rate. Conversely, during the second wave, the case/infection fatality rate we could compute waned to a much lower value of 2.2%. The most plausible explanation for this discrepancy is the hybrid nature of the latter estimate, due to the different policy for SARS-CoV-2 infection assessment. In fact, during the first wave only suspected cases due to travelling from high risk countries or with symptoms suggesting of COVID-19 were tested (55), while during the second waves also asymptomatic cases underwent swab testing. These findings appear to be confirmed by the assessment of the infection-fatality rate estimated through seroprevalence data, almost identical to COVID-19 fatality during the second wave, with the same overall national value of 2.2%. In addition, the comparison of the COVID-19 fatality rates in other European countries demonstrated generally a higher case-fatality rate for Italy during the first wave, and a marked decrease during the second wave that could have been at least partially due to the increase of population screening with SARS-CoV-2 swab testing of a large proportion of asymptomatic individuals (55). However, since the availability of SARS-CoV-2 molecular testing increased all over Europe during the second wave, our results may also indicate that the severity of the disease and the spread of the infection decreased in Italy with time during 2020, as compared with the other European countries, for reasons possibly related to the higher severity of the first wave, such as a larger prevalence of immunity in the population, or the increased depletion of highly susceptible individuals due to the high first wave COVID-19 mortality (56-59). Interestingly, our results are partially conflicting with data from a recent meta-analysis suggesting much lower value (2.7%) during the first wave in European region (33) but higher estimates for Italy with a mean value of 7.8% (median=8.58%) and range from 1.7% up to 14.5%. This high heterogeneity could be explained by the modality of case-fatality assessment among different studies. In particular, the lower value was reported from a study implementing modelling techniques, e.g. SEIR (Susceptible-Exposed-Infective-Recovered) model (60), as well as when based on incomplete data when the first wave was still ongoing (61). Conversely, studies using real and comprehensive data demonstrated similar or even higher estimates compared with the present study (62-64). Interestingly, a comparable pattern of discrepancies in the estimation of case-fatality rate can be noted also for other countries severely hit by the pandemic such as United Kingdom and France (33). For these reasons, despite such modelling demonstrated a high reliability in the prediction of pandemic tend/curves (65,66), the estimation of disease case-fatality was not so effective and reliable, also since that the number of infections and deaths may be affected by other determinants, in particular the advances in SARS-CoV-2 infection as well as COVID-19 diagnosis (67), and especially treatment (68-70). The occurrence of a high case-fatality rate in Italy was not entirely unexpected, being explained by the demographic and health characteristics of the Italian population. Also, at the very beginning of the pandemic in Italy, a case-fatality rate of 7.2% was estimated by the National Institute of Health (71), much higher compared with the one reported in China (72). Indeed, COVID-19 demonstrated to be more severe and deadly in vulnerable individuals due to older age and/or comorbidities (73,74), leading to a higher mortality in older subjects (75). Similarly, our findings are consistent with the recent report of the National Institute of Statistics, as they found a slightly higher (sex and age-adjusted) case-fatality rate of 4.3% in the entire 2020 (52). Consistently with our findings, such analysis yielded a higher value in the first pandemic period (although based on a slightly different timeframe, February-May 2020), i.e. 6.6%, a lower value in June-September (1.5%), and again a slightly higher value in October (2.4%). Results of the seroprevalence nationwide survey confirmed that some Northern Italy areas were heavily affected during the first wave (76), especially the provinces of Bergamo, Brescia, Lodi, Cremona in Lombardy region, and Piacenza and Parma in Emilia-Romagna region (14). Such provinces were those that experienced the highest decrease in the hybrid case/infection fatality rate we could compute for the second wave, consistently with a pattern we have documented for COVID-19 incidence (14). Our results indicated that the case-fatality rate of COVID-19 was much higher as compared with influenza through 2020 and independently from the time period, indicating that COVID-19 should not be considered a simply flu-like syndrome (77,78), with much larger implications in terms of population and public health burden. This further confirms how relevant is the implementation of effective preventive medicine measures against SARS-CoV-2 infection and COVID-19 including but not limited to vaccination, also in the absence of most effective therapy for this disease (79). Finally, our findings are particularly relevant from a public health perspective since they highlight how different was the impact of the COVID-19 pandemic compared to the seasonal flu and other outbreaks, taking into account the number of affected people and deaths, the health care systems overload, and the psychological and economic burden (80-82). Our study has some limitations. First, we used aggregated data at a provincial level, showing much higher level of geographical detail than the previous ‘regional’ analyses but still not entirely homogeneous in terms of population size characteristics, despite we tried to control for some potential confounders. In addition, we could not calculate sex- and age-standardized estimates, and therefore the comparison across different geographical areas must be made with caution (83). Strengths of our analysis include the assessment of the COVID-19 severity during the first two pandemic waves when there was no circulation of virus variants (43), making unlikely this possible confounding related to differences in virus transmission and severity (84,85). Similarly, the vaccination campaign effectively began in January 2021 (86), thus not affecting the susceptibility of subjects and the reliability of our analysis.

Conclusions

Our findings demonstrate that COVID-19 severity in Italy, as assessed through either case-fatality or infection-fatality rates, has been much higher compared with other airborne infections like influenza, while being substantially similar to a few other Western European countries. They also indicate that COVID-19 case-fatality rate and infection fatality rate substantially differ, though such measures are difficult to assess, due to methodological issues and potential biases that can affect these estimates. An adequate assessment of COVID-19 severity may also be of major relevance to plan and test public health interventions aimed at curbing the spread of SARS-CoV-2 infection.
  64 in total

1.  2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution.

Authors:  Manuel Battegay; Richard Kuehl; Sarah Tschudin-Sutter; Hans H Hirsch; Andreas F Widmer; Richard A Neher
Journal:  Swiss Med Wkly       Date:  2020-02-07       Impact factor: 2.193

2.  Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.

Authors:  Rossella Porcheddu; Caterina Serra; David Kelvin; Nikki Kelvin; Salvatore Rubino
Journal:  J Infect Dev Ctries       Date:  2020-02-29       Impact factor: 0.968

3.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Authors:  Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2020-05-29       Impact factor: 19.103

4.  Associations between mortality from COVID-19 in two Italian regions and outdoor air pollution as assessed through tropospheric nitrogen dioxide.

Authors:  Tommaso Filippini; Kenneth J Rothman; Silvia Cocchio; Elena Narne; Domenico Mantoan; Mario Saia; Alessia Goffi; Fabrizio Ferrari; Giuseppe Maffeis; Nicola Orsini; Vincenzo Baldo; Marco Vinceti
Journal:  Sci Total Environ       Date:  2020-11-04       Impact factor: 7.963

5.  SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy.

Authors:  Marco Vinceti; Tommaso Filippini; Kenneth J Rothman; Silvia Di Federico; Nicola Orsini
Journal:  Environ Res       Date:  2021-04-01       Impact factor: 8.431

Review 6.  Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review).

Authors:  Daniela Calina; Anca Oana Docea; Demetrios Petrakis; Alex M Egorov; Aydar A Ishmukhametov; Alexsandr G Gabibov; Michael I Shtilman; Ronald Kostoff; Félix Carvalho; Marco Vinceti; Demetrios A Spandidos; Aristidis Tsatsakis
Journal:  Int J Mol Med       Date:  2020-05-06       Impact factor: 4.101

7.  Effectiveness of the measures to flatten the epidemic curve of COVID-19. The case of Spain.

Authors:  Marc Saez; Aurelio Tobias; Diego Varga; Maria Antònia Barceló
Journal:  Sci Total Environ       Date:  2020-04-18       Impact factor: 7.963

8.  COVID-19 deaths in Lombardy, Italy: data in context.

Authors:  Anna Odone; Davide Delmonte; Thea Scognamiglio; Carlo Signorelli
Journal:  Lancet Public Health       Date:  2020-04-25

9.  Neurological comorbidity and severity of COVID-19.

Authors:  Alberto Romagnolo; Roberta Balestrino; Gabriele Imbalzano; Giovannino Ciccone; Franco Riccardini; Carlo Alberto Artusi; Marco Bozzali; Bruno Ferrero; Elisa Montalenti; Elisa Montanaro; Mario Giorgio Rizzone; Giovanna Vaula; Maurizio Zibetti; Leonardo Lopiano
Journal:  J Neurol       Date:  2020-08-04       Impact factor: 4.849

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  6 in total

1.  Emergency Medical Services Calls Analysis for Trend Prediction during Epidemic Outbreaks: Interrupted Time Series Analysis on 2020-2021 COVID-19 Epidemic in Lazio, Italy.

Authors:  Antonio Vinci; Amina Pasquarella; Maria Paola Corradi; Pelagia Chatzichristou; Gianluca D'Agostino; Stefania Iannazzo; Nicoletta Trani; Maria Annunziata Parafati; Leonardo Palombi; Domenico Antonio Ientile
Journal:  Int J Environ Res Public Health       Date:  2022-05-13       Impact factor: 4.614

2.  Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.

Authors:  Stefania Paduano; Pasquale Galante; Nausicaa Berselli; Luca Ugolotti; Alberto Modenese; Alessandro Poggi; Marcella Malavolti; Sara Turchi; Isabella Marchesi; Roberto Vivoli; Paola Perlini; Rossana Bellucci; Fabriziomaria Gobba; Marco Vinceti; Tommaso Filippini; Annalisa Bargellini
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

3.  A deep learning approach for Spatio-Temporal forecasting of new cases and new hospital admissions of COVID-19 spread in Reggio Emilia, Northern Italy.

Authors:  Veronica Sciannameo; Alessia Goffi; Giuseppe Maffeis; Roberta Gianfreda; Daniele Jahier Pagliari; Tommaso Filippini; Pamela Mancuso; Paolo Giorgi-Rossi; Leonardo Alberto Dal Zovo; Angela Corbari; Marco Vinceti; Paola Berchialla
Journal:  J Biomed Inform       Date:  2022-07-11       Impact factor: 8.000

4.  Italian National Recovery and Resilience Plan: a Healthcare Renaissance after the COVID-19 crisis?

Authors:  Tommaso Filippini; Silvio Roberto Vinceti
Journal:  Acta Biomed       Date:  2021-11-17

Review 5.  Zinc and selenium supplementation in COVID-19 prevention and treatment: a systematic review of the experimental studies.

Authors:  Erica Balboni; Federico Zagnoli; Tommaso Filippini; Susan J Fairweather-Tait; Marco Vinceti
Journal:  J Trace Elem Med Biol       Date:  2022-02-18       Impact factor: 3.995

6.  Revising the legislation of Ethics Committees to ease biomedical research in humans across the world: lessons from the COVID-19 emergency.

Authors:  Silvio Roberto Vinceti; Tommaso Filippini
Journal:  Acta Biomed       Date:  2022-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.